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The  strategies  employed  in chromatography  steps  play  a key  role  in  downstream  processes  for  mono-
clonal  antibody  (mAb)  manufacture.  This  work  addresses  the  integrated  optimisation  of chromatography
step  sequencing  and  column  sizing  in mAb  puriﬁcation  processes.  Chromatography  sequencing  decisions
include  the  resin  selection  at  each  typical  step,  while  the column  sizing  decisions  include  the  number  of
columns,  the  column  diameter  and  bed  height,  and  number  of  cycles  per  batch.  A mixed  integer  nonlinear
programming  (MINLP)  model  was  developed  and then  reformulated  as a mixed  integer  linear  fractional
programming  (MILFP)  model.  A  literature  approach,  the  Dinkelbach  algorithm,  was  adopted  as  the  solu-iopharmaceutical manufacturing
rocesses
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hromatography puriﬁcation
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ILFP
tion method  for the MILFP  model.  Finally,  an industrially-relevant  case  study  was  investigated  for  the
applicability  of  the  proposed  models  and  approaches.
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. Introduction
The biopharmaceutical industry has been a rapidly growing
ector during the past decade. Accounting for 15.6% of the total
harmaceutical market, the global biopharmaceutical market value
eached $138 billion in 2011, and is expected to be over $320 bil-
ion by 2020 (GBI Research, 2012). Monoclonal antibodies (mAbs)
re emerging therapies that have been widely used to treat can-
er and autoimmune diseases. Yet mAb  manufacturers are faced
ith increased upstream productivities and puriﬁcation capacity
onstraints that can result in puriﬁcation bottlenecks. Hence it is
mportant to address how to ﬁnd the most cost-effective puriﬁca-
ion processes (Low et al., 2007; Langer, 2009; Pujar et al., 2009).
A key decision for mAb  puriﬁcation is the selection of the
hromatography sequence. There usually exist multiple chro-
atography steps in the mAb  puriﬁcation process, and each step
as a number of suitable candidate resins/types for selection.
he candidate resins often have different characteristics, e.g.,
ield, price, dynamic binding capacities. Here an importation
ssue is how to choose the best combination of resins/types for
∗ Corresponding author. Tel.: +44 20 76792563; fax: +44 20 73832348.
E-mail address: l.papageorgiou@ucl.ac.uk (L.G. Papageorgiou).
ttp://dx.doi.org/10.1016/j.compchemeng.2014.05.005
098-1354/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article uall chromatography steps to be of most beneﬁt to the whole
downstream process. Also, at each chromatography step, another
key decision is the column sizing strategy, e.g. opting to run a
smaller column for several cycles so as to reduce resin costs or a
large column for fewer cycles so as to save time and labour costs.
Decisions on the chromatography column sizes include the selec-
tion, the bed height and diameter of each column and the number
of cycles to run and the number of columns to use in parallel.
Recently, many computer-based decisional tools for the bio-
process sector have been developed (Farid et al., 2005; Lim et al.,
2006; Chhatre et al., 2006; Farid et al., 2007; Pollock et al., 2013a),
and some models have been proposed to assess different solu-
tions for the design and operation of chromatography steps (Joseph
et al., 2006; Chhatre et al., 2007; Chan et al., 2008; Stonier et al.,
2012; Simaria et al., 2012; Pollock et al., 2013b; Allmendinger et al.,
2012, 2013; Bentely and Kawajiri, 2013). Also, mathematical pro-
gramming models and frameworks have been widely applied to
optimisation problems in the pharmaceutical and biopharmaceu-
tical industries, e.g., capacity planning (Papageorgiou et al., 2001;
Levis and Papageorgiou, 2004) and production planning (Lakhdar
et al., 2005, 2007). At the process level, a number of mathemat-
ical programming optimisation models were developed to ﬁnd
the optimal puriﬁcation sequences, using physicochemical data of
protein mixtures and mathematical correlations of the separation
techniques. Vasquez-Alvarez et al. (2001) and Vasquez-Alvarez and
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Notation
Indices
bf bulk ﬁll step
h harvest step
i column size
j column number
k cycle number
n digit of the binary representation
r resin
s step
t resin type
ufdf ultraﬁltration step
vf virus ﬁltration step
vi virus inactivation step
Sets
BER set of resins in bind-elute mode
CS set of chromatography steps = capture, intermediate
puriﬁcation, polishing
FTR set of resins in ﬂow-through mode
Rs set of resins suitable to step s
Rt set of resins of the resin type t
Parameters
a, b, c utilities cost coefﬁcients
aot annual operating time, day
bcvr buffer usage of resin r, CV
bpc buffer price, £/L
brc bioreactor cost, £
brf scale-up factor of bioreactor cost
brn number of bioreactors
brt bioreaction time, day
brv bioreactor volume, L
ccsi column cost of size i at chromatography step s, £
cf scale-up factor of column cost
cvsi volume of column size i at step s, L
cysr product yield of resin r at chromatography step s
dbcr dynamic binding capacity of resin r, g/L
dmsi diameter of column size i at chromatography step s,
L
don number of operators for downstream processing
dvrs diaﬁltration volume ratio of step s
ecvr elute volume of resin r, CV
el equipment lifetime, year
fconc ﬁnal concentration of product, g/L
fvrs ﬂush volume ratio of step s
gef general equipment factor
gu unit general utilities cost, £/L
hsi height of column size i at chromatography step s, cm
i insurance cost ratio to the ﬁxed capital investment
js maximum number of columns at chromatography
step s, maxcns
ks maximum number of cycles at chromatography step
s, maxcyns
lr life time of resin r, cycle
lang Lang factor
maxbn maximum number of batches
maxbbv maximum buffer volume per batch
maxcns maximum number of columns at chromatography
step s
maxcyns maximum number of cycles at chromatography
step s
maxpvs maximum product volume at step s
ma maintenance cost ratio to the ﬁxed capital invest-
ment
mepc media price, £/L
mi miscellaneous material cost ratio to chemical
reagent and consumable costs
m  management cost ratio to direct labour cost
ncys product yield of non-chromatography step s
nvrs neutralisation volume ratio of step s
oe other equipment cost ratio to the bioreactor volume
of overpacking factor for resin
q maximum digit number in the binary representa-
tion of number of batches, (log2 maxbn)
q QCQA cost ratio to direct labour cost
r interest rate
rpcr resin price of resin r, £/L
refbrc reference cost of bioreactor, £
refbrv reference volume of bioreactor, L
refcc reference cost of column, £
refdm reference diameter of column, cm
sfd duration per shift, h
sfn number of shifts per day
st seed train bioreaction time, day
s supervisors cost ratio to direct labour cost
titre product titre, g/L
t tax cost ratio to the ﬁxed capital investment
uon number of operators per bioreactor in upstream
processing
velr linear velocity of ﬂow for resin r, cm/h
w wage of an operator, £/h
wt DSP window
˛ bioreactor working volume ratio
 media overﬁll allowance
 chromatography resin utilisation factor
 batch success rate
Continuous variables
ABV annual buffer volume, L
AC annual cost, £
AP annual product output, g
AT annual downstream operating time, day
BATs time for adding buffer per batch at chromatography
step s, min
BBV buffer volume added per batch, L
BC buffer cost, £
BT downstream processing time per batch, day
BVs buffer volume per batch at step s, L
CAC capital cost, £
CC consumables cost, £
CRC chemical reagents cost, £
DLC direct labour cost, £
FCI ﬁxed capital investment, £
GUC general utility cost, £
IC insurance cost, £
LC labour cost, £
M0 initial product mass entering downstream pro-
cesses per batch, g
Ms product mass per batch remaining after step s, gmaxcv maximum column volume at chromatography steps
sMAC  maintenance cost, £
MC  management cost, £
S. Liu et al. / Computers and Chemical 
MEC  media cost, £
MIC  miscellaneous material cost, £
OBJ optimisation objective, COG/g, £/g
OIC other indirect costs, £
PLTs time for loading product per batch at chromatogra-
phy step s, min
PV0 initial product volume entering downstream pro-
cesses per batch, L
PVs product volume per batch leaving step s, L
QC QCQA cost, £
RVs resin volume required at chromatography step s, L
SC supervisors cost, £
Ts processing time per batch of step s, min
TC tax cost, £
TCVs total column volume at chromatography step s, L
UC utilities cost, £
VFRs volumetric ﬂow rate at chromatography step s,
L/min
Binary variables
Usr 1 if resin r is selected for chromatography step s; 0
otherwise
Wsij 1 if there are j columns of size i at chromatography
step s; 0 otherwise
Xsi 1 if columns of size i is selected for chromatography
step s; 0 otherwise
Ysk 1 if there are k cycles during chromatography step
s; 0 otherwise
Zn 1 if the nth digit of the binary representation of vari-
able BN is equal to 1; 0 otherwise
Integer variables
BN number of completed batches
CNsi number of column size i at chromatography step s
CYNs number of cycles at chromatography step s
Auxiliary variables
UMs−1,r ≡ Usr · Ms−1
UVs−1,r ≡ Usr · PVs−1
UWTsrij ≡ Usr · Wsij · PLTs
UXsri ≡ Usr · Xsi
UXYsrik ≡ Usr · Xsi · Ysk
UYVsrk ≡ Usr · Ysk · TCVs
YVsk ≡ Ysk · TCVs
ZTn ≡ Zn · BT
ZVn ≡ Zn · BBV
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into (2004) developed two mixed integer linear programming
MILP) models for the optimal synthesis of multistep puriﬁca-
ion processes for a speciﬁed purity and recovery. Simeonidis
t al. (2005) and Natali et al. (2009), respectively, developed
ixed integer nonlinear programming (MINLP) and MILP mod-
ls to predict the behaviour and design of peptide-fusion tags
hat alter the puriﬁcation of proteins. Vasquez-Alvarez and Pinto
2003) extended their previous work by developing an MILP
odel for the synthesis of protein puriﬁcation processes that
ncorporates product losses assuming discrete percentage levels
roduct collection. Then, Polykarpou et al. (2011) incorporated
oth starting and ﬁnishing cut-points for each chromatographic
tep as optimisation decision variables. Later, this work was
xtended by developing efﬁcient MILP models with the discreti-
ation approximation (Polykarpou et al., 2012a) and piecewiseEngineering 68 (2014) 151–164 153
linearisation approximation (Polykarpou et al., 2012b) to overcome
the computational difﬁculty of MINLP models. These models use the
number of chromatography steps, purity and yield as performance
metrics, but do not account for the cost of the process. For the opti-
misation of the chromatography steps in the mAb production, Liu
et al. (2013a) developed an MILP model for the optimal column siz-
ing decisions. Then this work was  extended to MINLP models for
both facility design and facility ﬁt (Liu et al., 2013b).
However, to the best of our knowledge, no work has been done
to integrate the optimisation of decisions on chromatography step
sequences and columns sizes using mathematical programming
techniques. The work in this paper aims to incorporate the chro-
matography step sequencing decisions into our previous model (Liu
et al., 2013a,b), and to develop mathematical programming mod-
els and approaches for the optimisation of the downstream mAb
puriﬁcation process.
The rest of this paper is organised as follows: Section 2 describes
the problem considered in this work. The mathematical formula-
tion of the proposed MINLP model is presented in Section 3. Then,
the model is reformulated as a mixed integer linear fractional pro-
gramming (MILFP) model and a literature algorithm is adapted
for solution, as detailed in Section 4. In Section 5, an industrially-
relevant case study of mAb  production is presented, followed by
the computational results and discussion in Section 6. Finally, the
concluding remarks are drawn in Section 7.
2. Problem statement
This work focused on determining the optimal column sizing
strategies and chromatography steps sequencing strategies for a
mAb  puriﬁcation process. A typical mAb platform process was  used
in this study, as shown in Fig. 1. In the upstream processing (USP)
mammalian cells expressing the mAb  of interest are cultured in
bioreactors. In the downstream processing (DSP), the mAb  is recov-
ered, puriﬁed and cleared from viruses by a variety of operations,
including a number of chromatography steps. A typical three-
step chromatography sequence was considered, including three
packed-bed chromatography steps, for product capture, interme-
diate puriﬁcation and polishing, respectively (Fig. 1).
For the above three chromatography steps, it is important to
determine the resins to be used. There are a number of candidate
chromatography resins of different types for selection, with dif-
ferent suitability, yields, dynamic binding capacities, prices, linear
velocities and buffer volume usages. In order to ensure that ortho-
gonal separation mechanisms were used in the puriﬁcation process,
it was  assumed that each resin type can only be used once, i.e. no
two resins of the same type could be used in one sequence. For
example, considering two resins of the same type, A and B, suitable
for both capture and intermediate puriﬁcation steps, if resin A has
been used in the capture step, then resin B cannot be used at the
intermediate puriﬁcation step.
Furthermore, the chromatography column sizing strategy at
each chromatography step was determined, including the bed
height, diameter, number of cycles and number of columns to run
in parallel at each step. The selected strategy has a direct impact
on key metrics related to cost, time and annual product output.
For both the bed heights and diameters, some typical ranges with
discrete candidate values were available for selection, while the
number of cycles and number of columns per step were limited by
speciﬁc predetermined upper bounds.
In this problem, several scenarios with multiple USP trains
feeding a single DSP train were investigated. The cost of goods per
gram (COG/g) was  considered as the criterion for this problem,
equalling the cost of goods (COG), comprising of both capital-
related costs and operating costs, divided by the product output.
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his is a standard approach (Farid et al., 2005), which allows the
ncorporation of multiple process features into a single metric.
OG/g, as an objective function, prefers the solutions with higher
roduction output values.
Overall, the optimisation problem considered in this work is
escribed as follows:
Given are:
process sequence of a mAb  product;
number of USP trains, bioreactor volume and product titre;
candidate chromatography resins per step, and their key param-
eters (e.g. yield, linear velocity, buffer usage, dynamic binding
capacity);
key parameters of non-chromatography steps (e.g. yield, time,
buffer usage);
cost data (e.g., reference equipment costs, labour wage, resin,
buffer and media prices); and
candidate column diameters and heights, and the maximum
number of cycles and columns.
Determine:
chromatography step sequencing strategy (i.e., resin for each
step);
chromatography column sizing strategy (i.e. column diameter
and height, the number of cycles, number of columns per step) of
the resin used at each chromatography step;
number of total completed batches;
annual total processing time;
annual total production output; and
annual total cost.
So as to:
minimise COG/g, equalling the total annual cost divided by the
otal production output.
. MINLP model
In this section, an MINLP model, extended from our previous
ork (Liu et al., 2013b), is developed for the integrated chro-
atography sequencing and column sizing optimisation problem
escribed above. In the mathematical formulation of the developed
odel, the parameters are represented by lower case letters, while
he variables are represented by upper case letters.
.1. Chromatography Sequence
For the three packed-bed chromatography steps (capture, inter-
ediate puriﬁcation, polishing) considered, among all candidateuitable resins, only one resin can be used at each step.
r ∈ Rs
Usr = 1, ∀S ∈ CS (1)ufacturing process.
Due to the assumption given in the previous section that no two
resins of the same type should be used in any sequence, at most
one resin of each resin type can be used.
∑
s ∈ CS
∑
r ∈ Rs∩Rt
Usr ≤ 1, ∀t (2)
3.2. Protein mass
For each batch, the initial product protein mass entering into the
downstream processes depends on the titre of the product, titre,
and the working volume of production bioreactor, which is equal
to the working volume ratio, ˛, multiplied by the single bioreactor
volume, brv.
M0 = titre ·  ˛ · brv (3)
The product protein mass remaining after step s is equal to the
product mass entering into this step, i.e., the mass remaining after
the previous step s − 1, multiplied by the corresponding yield of
step s.
Ms = ncys · Ms−1, ∀S /∈ CS (4)
Ms =
∑
r ∈ Rs
(cysr · Usr) · Ms−1, ∀S ∈ CS (5)
where Eq. (4) is for the non-chromatography steps, while Eq. (5) is
for chromatography steps.
The annual product output is the amount of product produced
per year by the facility, determined by the product mass remaining
after the bulk ﬁll step per batch, Ms, multiplied by the number of
completed batches, BN,  and by the batch success rate, .
AP =  · BN · Ms, ∀s = bf (6)
The number of completed batches, BN,  is limited by an upper
bound given by Eq. (7):
BN ≤ maxbn (7)
where the maximum number of batches maxbn = brn ·⌊
(aot − st)/brt
⌋
, in which aot is the annual operating time; st
is the seed train bioreaction time; brt is the bioreaction time;
and brn is the number of bioreactors, i.e., the number of USP
trains.
3.3. Resin volume
The total column volume of chromatography step s is given by
the number of columns multiplied by the corresponding single col-
umn  volume.
TCVs =
∑
cvsi · CNsi, ∀s ∈ CS (8)
i
where cvsi is the volume (L) of the candidate column size i at chro-
matography step s, determined by speciﬁc diameter dmsi and height
hsi (cm). Thus, if a column size i is selected, both corresponding
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iameter and bed height will be known. Here, it is assumed that
nly one column size can be selected at each chromatography step:
i
Xsi = 1, ∀s ∈ CS (9)
Nsi ≤ maxcns · Xsi ∀s ∈ CS, i (10)
here Xsi is a binary variable to indicate whether column size i is
elected at chromatography step s, and maxcns is the maximum
umber of columns at chromatography step s.
The total amount of resin available at each chromatography step
ust be sufﬁcient to process all protein mass entering into that
tep. Thus, the number of cycles multiplied by the total column
olume should be no less than the required resin volume.
YNs · TCVs≥RVs, ∀s ∈ CS (11)
here the amount of resin required per batch at chromatography
tep s, RVs, is determined by the mass of product to be processed,
s−1, the dynamic binding capacity of the selected resin, dbcr, and
he resin utilisation factor, :
Vs = Ms−1
 ·
∑
r ∈ Rs (dbcr · Usr)
,  ∀s ∈ CS (12)
Also, the number of cycles at each chromatography step cannot
xceed an upper bound, maxcyns:
YNs ≤ maxcyns, ∀s ∈ CS (13)
.4. Flow rate
Volumetric ﬂow rate (L/min) at each chromatography step is
qual to the velocity for the selected resin, velr, multiplied by the
elected column diameter, dmsi. In order to keep units consistency,
onversion factors have been applied:
FRs = 11000 ·
1
60
·
∑
r ∈ Rs
(velr · Usr)
·
∑
i
 ·
(
dmsi
2
)2
· Xsi, ∀s ∈ CS (14)
here velr is the linear ﬂow velocity in cm/h given for resin r.
.5. Product and buffer volume
The initial product volume entering downstream processes
or each batch, PV0, equals the working volume of one biore-
ctor, i.e., the bioreactor volume multiplied by working volume
atio.
V0 =  ˛ · brv (15)
The product volume remaining after harvest step, PVs for s = h,
s equal to the initial product volume plus the ﬂush volume, where
he ﬂush volume equals the ﬂush volume ratio, fvrs, multiplied by
he initial product volume.
Vs = (f vrs + 1) · PV0, ∀s = h (16)
While the required buffer material volume used in the harvest
tep, BVs for s = h, is equal to the ﬂush volume:
Vs = f vrs · PV0, ∀s = h (17)
The product volume remaining after each chromatography step,
Vs for s ∈ CS,  is equal to the eluate volume at this step if the resin
s in the bind-elute mode (BER), or the product volume remaining
fter the previous step if the resin is in the ﬂow-through modeEngineering 68 (2014) 151–164 155
(FTR). Here, the eluate volume is proportional to the product of the
number of cycles and the total column volume:
PVs =
∑
r ∈ Rs∩BRE
(ecvr · Usr) · CYNs · TCVs
+
∑
r ∈ Rs∩FTR
(Usr) · PVs−1, ∀s ∈ CS (18)
where ecvr is the eluate volume ratio of resin r. Moreover, the
required buffer material volume, BVs, is also proportional to the
product of the number of cycles and the total column volume:
BVs =
∑
r ∈ Rs
(bcvr · Usr) · CYNs · TCVs, ∀s ∈ CS (19)
where bcvr is the buffer volume ratio of resin r.
The product volume remaining after virus inactivation step, PVs
for s = vi,  is equal to the product volume entering into that step
plus the used neutralisation volume. Here, the neutralisation vol-
ume  equals the neutralisation volume ratio, nvrs, multiplied by the
product volume entering into that step.
PVs = (nvrs + 1) · PVs−1, ∀s = vi (20)
The required buffer volume used in virus inactivation step, BVs
for s = vi, is equal to the neutralisation volume:
BVs = nvrs · PVs−1, ∀s = vi (21)
Similar to the harvest step, the product volume remaining after
virus ﬁltration step, PVs for s = vf, is the product volume entering
into this step plus the ﬂush volume used:
PVs = (f vrs + 1) · PVs−1, ∀s = vf (22)
Meanwhile, the required buffer volume used in virus ﬁltration
step, BVs for s = vf,  is equal to the ﬂush volume:
BVs = f vrs · PVs−1, ∀s = vf (23)
The product volume remaining after UF/DF step, PVs for s = ufdf,
is equal to the remaining product mass divided by ﬁlling concen-
tration.
PVs = Ms
fconc
, ∀s = ufdf (24)
The buffer volume required at UF/DF step, BVs for s = ufdf, is
equal to the product volume remaining after that step, multiplied
by diaﬁltration volume ratio, dvrs.
BVs = dvrs · PVs, ∀s = ufdf (25)
The total required buffer volume, BBV, for each batch will simply
be equal to the summation of buffer volumes, BVs, used at different
steps:
BBV =
∑
s
BVs (26)
Thus, the annual total buffer volume, ABV, equals the number of
completed batch multiplied by the buffer volume per batch:
ABV = BN · BBV (27)
3.6. Processing time
In each chromatography step, the total processing time per
batch (min) is comprised of processing time for both adding buffer
and loading product.
Ts = PLTs + BATs, ∀s ∈ CS (28)
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The processing time for loading product, PLTs, is given by
he total product volume entering into the chromatography step
ivided by the number of columns, and by the volumetric ﬂow rate.
LTs = PVs−1
VFRs ·
∑
iCNsi
, ∀s ∈ CS (29)
It is worth noting that as for each chromatography step s, only
ne column size i is selected, CNsi is positive for only one size i based
n Eqs. (9) and (10). Thus,
∑
iCNsi in Eq. (29) is the number of the
elected columns at the step.
The processing time for adding buffer, PLTs, is given by the total
olume of buffer added in each cycle divided by the volumetric ﬂow
ate, then multiplied by the number of cycles.
ATs =
CYNs ·
∑
r ∈ Rs (bcvr · Usr) ·
∑
i(cvsi · Xsi)
VFRs
, ∀s ∈ CS (30)
As the non-chromatography steps are not the main concern in
his problem, it is assumed that their operating times are constant.
he processing time per batch, BT,  is the summation of processing
imes of all steps. In addition, the shift pattern of DSP operators is
onsidered to convert total DSP time into days.
T =
∑
sTs
60 · sfd · sfn (31)
here sfd is the duration of each shift (h), and sfn is the number of
hifts per day.
The annual DSP time, AT,  is equal to the number of completed
atch multiplied by the processing time per batch:
T = BN · BT (32)
Also, AT cannot exceed the annual available time for DSP:
T ≤ aot − st − brt (33)
.7. Costs
The total cost is categorised into two types: direct cost and indi-
ect cost, which are presented in the following two subsections,
espectively.
.7.1. Direct costs
We ﬁrstly consider the direct costs based on the resource utili-
ation, including labour, materials and utilities.
Labour cost
The labour cost, LC,  includes the direct labour cost, DLC, super-
isors cost, SC,  quality control and quality assurance (QCQA) cost,
C, and management cost, MC.
C = DLC + SC + QC + MC  (34)
The direct labour cost includes the costs for both USP and DSP. At
he USP stage, its direct labour cost is the calculated by the number
f operators per bioreactor, uon, hourly wage, w, bioreaction time,
rt, number of completed batches, BN,  while at the DSP stage, its
irect labour cost is the calculated by the number of operators per
hift, don, hourly wage, w, duration per shift, sfd,  number of shifts
er day, sfn,  and total processing time, AT:
LC = 24 · uon · w · brt · BN + don · w · sfd · sfn · AT (35)
All other three cost terms are assumed to be proportional to the
irect labour cost as follows:C = s · DLC (36)
C = q · DLC (37)
C  = m  · DLC (38)Engineering 68 (2014) 151–164
Materials cost
The materials cost was split into chemical reagents, consu-
mables and miscellaneous materials. The key materials related
to chromatography operations are the resins and buffers, which
typically dominate the puriﬁcation materials cost (e.g. >60% at com-
mercial scales) (Simaria et al., 2012; Pollock et al., 2013a) and so
these were considered explicitly under chemical reagents and con-
sumables. The chemical reagents cost also captured the bioreactor
media cost. The remaining materials were captured under miscel-
laneous materials.
Here, the chemical reagents cost, CRC, is assumed to include the
cost for buffer, BC,  and bioreactor media, MEC:
CRC = BC + MEC (39)
The buffer cost, BC,  is the total buffer required multiplied by the
buffer price, bpc.
BC = bpc · ABV (40)
The bioreactor media cost, MEC, is the total media required for
all batches multiplied by the media price, mepc.
MEC =  · mepc ·  ˛ · brv · BN (41)
where  is the media overﬁll allowance.
The key consumables cost, CC,  in this study is the resin cost that
is deﬁned as the total used resin volume multiplied by the resin
price, rpcr. The total resin volume used is equal to the total column
volume, multiplied by the number of cycles used (batch number
multiplied by cycle number per batch) divided by the resin’s life-
time, lr.
CC =
∑
r ∈ Rs
∑
s ∈ CS
of · rpcr · BN · CYNs · TCVs
lr
· Usr (42)
where of is the overpacking factor.
The miscellaneous material cost, MIC, is proportional to the sum-
mation of the chemical reagents cost and consumables cost.
MIC = mi · (CRC + CC) (43)
Utilities cost
Utilities cost, UC, includes the costs of steam, compressed air,
electricity, cooling water and water for injection (WFI). To simplify
the calculation of the utilities cost, according to Simaria et al. (2012),
the utilities considered in this work are separated into three parts:
the ﬁrst part is proportional to the total bioreactor volume, brn·brv;
the second part is related to the total batch sizes, i.e. number of
completed batches, BN,  multiplied by single bioreactor volume, brv;
while the third part involves the annual buffer volume, ABV. Thus,
the utilities cost can be expressed as the summation of three terms
as follows:
UC = a · brn · brv + b · brv · BN + c · ABV (44)
where a, b, c are given.
3.7.2. Indirect costs
Next, we  consider the indirect costs, including capital cost and
other indirect costs, both of which are dependent on the facilities.
Capital Cost
The annualised capital cost, CAC, is calculated by the ﬁxed capital
investment, FCI,  and the capital recovery factor:
CAC = FCI · r · (1 + r)
el
(1 + r)el − 1
(45)where r is the interest rate; el is the lifetime of the equipment in
years; and FCI is the ﬁxed capital investment, consisting of the capi-
tal investment for bioreactors, chromatography columns and other
equipment in DSP. As the decision for other equipment is not the
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ain concern of this work, the capital investment for other equip-
ent is assumed to be proportional to the bioreactor cost. Here,
he ﬁxed capital investment is approximated by Lang factor, lang
Farid et al., 2005). Also, the general equipment factor, gef,  is used to
ake into account the costs of support equipment, spares, utilities
quipment and vessels:
CI = lang · (1 + gef ) · (brn · brc
+
∑
s ∈ CS
∑
i
CCsi · CNsi + oe · brc · brn) (46)
For different sizes of chromatography columns and bioreactors,
he costs are calculated using the values of reference equipment
izes and costs to scale up the equipment cost, i.e., ccsi = refcc ·
dmcol/refdm)
cf
, brc = refbrc · (brv/refbrv)brf , where refcc is the cost
f a single chromatography column with a diameter of refdm,  and
efbrc is the cost of a single bioreactor with a volume of refbrv.  Both
eference costs are used to scale up the costs of chromatography
olumns and bioreactors with different sizes, using cf and brf as the
cale-up factors of column cost and bioreactor cost, respectively.
Other indirect costs
Other indirect costs considered here include the annual main-
enance cost, MAC, insurance cost, IC,  and local tax costs, TC,  which
re all assumed to be dependent on the ﬁxed capital investment,
espectively. Thus, these costs can be expressed by following equa-
ions:
AC  = ma · FCI (47)
C = i · FCI (48)
C = t · FCI (49)
The general utilities cost, GUC, is equal to the unit general util-
ties cost, gu,  multiplied by the total bioreactor volume, which is
qual to the number of bioreactors multiplied by the single biore-
ctor volume:
UC = gu · brn · brv (50)
Thus, we have the other indirect costs, OIC:
IC = MAC  + IC + TC + GUC (51)
According to the above equations, the annual total cost, AC,  is
alculated:
C = LC + CRC + CC + MIC  + UC + CAC + OIC (52)
.8. Objective function
In the work, the objective is to minimise COG/g, which equals
he annual total cost divided by the annual production output. Thus,
e have the following objective function:
BJ = AC
AP
(53)
Overall, the considered problem is formulated as an MINLP
odel with Eqs. (1)–(52) as constraints and Eq. (53) as the objective
unction, in which Eqs. (5), (6), (11), (12), (14), (18), (19), (27), (29),
30), (32), (42) and (53) are nonlinear equations.
. MILFP model
In general, MINLP models are difﬁcult to solve using standard
ommercial solvers so as to identify global optimal solutions or
ven feasible solutions. In this section, we reformulate the proposed
INLP model to overcome the computational difﬁculties. In the
roposed MINLP model, all nonlinearities involve the products or
ractions comprising of discrete variables. Only the nonlinearity ofEngineering 68 (2014) 151–164 157
the objective function is the fraction of two  continuous variables.
Thus, the proposed MINLP model can be reformulated as an MILFP
model, in which all the constraints are linear, and the objective
function is a fraction of two linear functions. Thus, in this section,
we present the MILFP model based on the proposed MINLP model
using exact linearisation techniques (Floudas, 1995; Harjunkoski
et al., 1998; Sherali and Adams, 1999).
4.1. Linearisation methods
To reformulate the proposed MINLP model as an MILFP model,
we need to linearise all the nonlinear constraints. If an integer vari-
able is involved in the nonlinearity, it should be expressed by a
number of auxiliary binary variables at ﬁrst. An arbitrary integer
variable I can be expressed by its decimal representation as follows:
I =
∑
l
l · El (54)
∑
l
El = 1 (55)
where El is a binary variable to indicate whether the value of
variable I is equal to l. Alternatively, the integer variable I can be
expressed by its binary representation:
I =
∑
m
2m−1 · Fm (56)
where Fm is a binary variable to indicate whether the mth digit of
the binary representation of the variable is equal to 1.
Thus, an integer variable is expressed by a set of binary variables
in both the above two  ways. Then, the bilinear term in the form
of the product of an integer variable and a nonnegative continu-
ous/integer variable is transformed into a series of multiplications
of a binary variable and a nonnegative continuous/integer variable.
Here, in order to linearise a bilinear term with a binary variable
and a nonnegative continuous variable, we  introduce an auxiliary
nonnegative variable, a big-M parameter and additional auxiliary
constraints. If the decimal representation is used to express an
integer variable (Eqs. (54) and (55)), the following two  constraints
should be added to express the product of binary variable El and
nonnegative continuous variable, C:
CEl ≤ M · El, ∀l (57)∑
l
CEl = C (58)
where CEl is an auxiliary variable, CEl ≡ C · El , and M is a large num-
ber, an upper bound of variable C.
If the binary representation is used to express an integer vari-
able (Eq. (56)), the following three constraints should be added to
express the product of binary variable Fm and nonnegative contin-
uous variable, C (Glover, 1975):
CFm ≤ M · Fm, ∀m (59)
CFm ≤ C, ∀m (60)
CFm≥C − M(1 − Fm), ∀m (61)
where, CFm is an auxiliary variable, CFm ≡ C · Fm.
Comparing the above two  representations used to linearise a
bilinear term involving an integer variable, if the maximum pos-
sible value of integer variable I is ı, then, |k| = , and |l| = (log2ı).
Thus, the binary representation of the integer variable requires
fewer binary variables. For the number of auxiliary constraints,
the binary representation method requires 3 × |l| = 3 × (log2) con-
straints, while the decimal representation requires |k| + 2 = ı + 2
constraints. Thus, when  is large (ı > 10), the binary representa-
tion is preferred, which saves both the number of constraints and
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he number of variables. When ı is small ( ≤ 10), the decimal rep-
esentation is better to be used, which requires a smaller number of
onstraints. In the proposed model, the integer variables involved
n the bilinear terms include CNsi, CYNs and BN.  As the maximum
umber of columns and cycles are small (≤10), we use the decimal
epresentation for CNsi and CYNs, while BN is expressed using its
inary representation, as its value can be very large (>100).
.2. Model reformulation
According to the above discussion, ﬁrstly, we express CNsi and
YNs by their decimal representations as follows:
Nsi =
∑js
j=1
j · Wsij, ∀s ∈ CS, i (62)
js
j=1
Wsij = Xsi, ∀s ∈ CS, i (63)
YNs =
∑ks
k=1
k · Ysk, ∀s ∈ CS (64)
ks
k=1
Ysk = 1, ∀s ∈ CS (65)
here Wsij indicates whether there are j columns of size i at chro-
atography step s, while Ysk indicates whether there are k cycles
uring chromatography step s. js and ks are the maximum values
f CNsi and CYNs for each chromatography step, respectively, i.e.,
s = maxcns, and ks = maxcyns.
Then, BN can be expressed by its binary representation:
N =
∑q
n=1
2n−1 · Zn (66)
here Zn indicates whether the nth digit of the binary representa-
ion of variable BN is equal to 1, and q = (log2maxbn).
Eq. (5) can be linearised using the following constraints by
ntroducing an auxiliary variable, UMs−1,r ≡ Usr · Ms−1:
Ms−1,r ≤ titre ·  ˛ · brv · Usr, ∀s ∈ CS, r ∈ Rs (67)
r ∈ Rs
UMs−1,r = Ms−1,r , ∀s ∈ CS (68)
s =
∑
r ∈ Rs
(ncysr · UMs−1,r), ∀s ∈ CS (69)
Based on Eq. (66), Eq. (6) is equivalent to the following equa-
ions:
P =
∑q
n=1
 · 2n−1 · ZMsn, ∀s = bf (70)
Msn ≤ titre ·  ˛ · brv · Zn, ∀s = bf, n = 1, . . .,  q (71)
Msn ≤ Ms, ∀s = bf, n = 1, . . .,  q (72)
Msn≥Ms − titre ·  ˛ · brv · (1 − Zn), ∀s = bf, n = 1, . . .,  q (73)
here the auxiliary variable ZMsn ≡ Zn · Ms.
Based on Eq. (64), Eq. (11) is equivalent to the following equa-
ions:
ks
k=1
k · YVsk≥RVs, ∀s ∈ CS (74)
Vsk ≤ maxcns · max  cvs · Ysk, ∀s ∈ CS, k = 1, . . .,  ks (75)
ks
k=1
YVsk = TCVs, ∀s ∈ CS (76)
here YVsk ≡ Ysk · TCVs, and maxcvs is the maximum column vol-
me  at chromatography step s.
Based on the equivalence of UMs−1,r and Usr · Ms−1 deﬁned by
qs. (68) and (69), Eq. (12) can be rewritten as the following equa-
ion:
Vs =
∑
r ∈ Rs
UMs−1,r
dbcr ·  , ∀s ∈ CS (77)Engineering 68 (2014) 151–164
By introducing an auxiliary variable UXsri ≡ Usr · Xsi, Eq. (14) can
be replaced by the following equations:
VFRs = 11000 ·
1
60
·
∑
r ∈ Rs
∑
i
velr ·  ·
(
dmsi
2
)2
· UXsri, ∀s ∈ CS
(78)
∑
r ∈ Rs
UXsri = Xsi, ∀s ∈ CS, i (79)
∑
i
UXsri = Usr, ∀s ∈ CS, r ∈ Rs (80)
We deﬁne auxiliary variables UYVsrk ≡ Usr · YVsk ≡ Usr · Ysk ·
TCVs, and UVs−1,r ≡ Usr · PVs−1, by the following constraints:
UYVsrk ≤ maxcns · maxcvs · Usr, ∀s ∈ CS, r ∈ Rs, k = 1, . . ., ks (81)∑
r ∈ Rs
UYVsrk = YVsk, ∀s ∈ CS, k = 1, . . .ks (82)
UVs−1,r ≤ maxpvs−1 · Usr, ∀s ∈ CS, r ∈ Rs (83)∑
r ∈ Rs
UVs−1,r = PVs−1, ∀s ∈ CS (84)
Then, based on Eq. (64), Eqs. (18) and (19) can be rewritten as:
PVs =
∑
r ∈ Rs∩BER
∑ks
k=1
ecvr · k · UYVsrk
+
∑
r ∈ Rs∩FTR
· UVs−1,r , ∀s ∈ CS (85)
BVs =
∑
r ∈ Rs
∑ks
k=1
bcvr · k · UYVsrt, ∀s ∈ CS (86)
Replacing BN by Eq. (66), and introducing an auxiliary variable
ZVn = Zn · BBV , Eq. (27) can be expressed as:
ABV =
∑q
n=1
2n−1 · ZVn (87)
ZVn ≤ maxbbv · Zn, ∀n = 1, . . .,  q (88)
ZVn ≤ BBV, ∀n = 1, . . .,  q (89)
ZVn≥BBV − maxbbv · (1 − Zn), ∀n = 1, . . .,  q (90)
According to a newly introduced auxiliary variable UWTsrij ≡
Usr · Wsij · PLTs and Eq. (62), we have the following constraints to
replace Eq. (29):
1
1000
· 1
60
·
∑
r ∈ Rs
∑
i
∑js
j=1
velr ·  ·
(
dmsi
2
)2
·j · UWTsrij = PVs−1, ∀s ∈ CS (91)
UWTsrij ≤ brt · Wsij, ∀s ∈ CS, r ∈ Rs, i, j = 1, . . .,  js (92)
UWTsrij ≤ brt · Usr, ∀s ∈ CS, r ∈ Rs, i, j = 1, . . .,  js (93)
∑
i
∑js
j=1
∑
r ∈ Rs
UWTsrij = PLTs, ∀s ∈ CS (94)
Here, we introduce another auxiliary variable UXYsrik ≡ UXsri ·
Ysk ≡ Usr · Xsi · Ysk, and the following constraints are equivalent to
Eq. (30) with the existence of Eq. (64):
BATs =
∑
r ∈ Rs
∑
i
∑ks
k=1
bcvr · cvsi · k · UXYsrik
(1/1000) · (1/60) · vels · (dmsi/2)2
,
∀s ∈ CS (95)∑
r ∈ Rs
∑
i
UXYsrik = Ysk, ∀s ∈ CS, k = 1, . . .,  ks (96)
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ks
k=1
UXYsrik = UXsri, ∀s ∈ CS, r ∈ Rs, i (97)
Let ZTn ≡ Zn · BT ,  due to Eq. (66), Eq. (32) can be rewritten as:
T =
∑q
n=1
2n−1 · ZTn (98)
Tn ≤ (aot − st − brt) · Zn, ∀n = 1, . . .,  q (99)
Tn ≤ BT, ∀n = 1, . . .,  q (100)
Tn≥BT − (aot − st − brt)  · (1 − Zn), ∀n = 1, . . .,  q (101)
Finally, we introduce auxiliary variables ZUYVsrkn ≡
n · UYVsrk ≡ Usr · YVsk ≡ Usr · Ysk · TCVs. Thus, due to Eq. (66),
q. (42) can be reformulated as:
C =
∑
s ∈ CS
∑
r ∈ Rs
∑q
n=1
∑ks
k=1
of · rpcr · 2n−1 · k · ZUYVsrkn
lr
(102)
UYVsrkn ≤ max  tcvs · Zn, ∀s ∈ CS, r ∈ Rs, k = 1, . . .,  ks, n = 1, . . .,  q
(103)
UYVsrkn ≤ UYVsrk, ∀s ∈ CS, r ∈ Rs, k = 1, . . .,  ks, n = 1, . . .,  q (104)
UYVsrkn ≤ UYVsk − maxtcvs · (1 − Zn),
∀s ∈ CS, r ∈ Rs, k = 1, . . .,  ks, n = 1, . . .,  q (105)
After the above reformulation, the original MINLP model is
eformulated with Eqs. (1)–(4), (7)–(10), (13), (15)–(17), (20)–(26),
28), (31), (33)–(41), (43)–(52), (62)–(105) as constraints with Eq.
53) as the objective function. In this model, all constraints are
inear and the objective function is a fraction of two  continuous
ariables. Thus, it is an MILFP model.
.3. Dinkelbach algorithm
Now, we apply the Dinkelbach algorithm to the above developed
ILFP model. The Dinkelbach algorithm, developed by Dinkelbach
1967), is an application of the classical Newton method to solve
onvex nonlinear fractional programming (NFP) models by solving
 sequence of nonlinear programming (NLP) models successively.
ecently, several works have implemented the Dinkelbach algo-
ithm to solve MILFP problems (Bradley and Arntzen, 1999; Pochet
nd Warichet, 2008; You et al., 2009; Billionnet, 2010; Espinoza
t al., 2010; Trinh et al., 2012; Yue and You, 2013).
For an optimisation problem max{ (x)/(x)
∣∣ x ∈ ˝},  where (x)
nd (x) are two linear functions, and  is the variable x’ feasible
egion, the Dinkelbach algorithm procedure is described as below:
Step 1: Initialise f;
Step 2: Solve the MILP problem max{ (x) − f · (x)|x ∈ ˝},  and the
optimal solution is denoted as x*;
Step 3: If | (x∗) − f · (x∗)| ≤ ε}, stop and x* is the optimal solution;
otherwise, update = ( (x∗))/((x∗)), and go to Step 2.It has been proven that the Dinkelbach algorithm can ﬁnd the
lobal optimal solution of the MILFP model for the maximisation
roblem (You et al., 2009). Similarly, it can be applied to the min-
misation optimisation model with the guarantee of the optimality.Fig. 2. Procedure of the Dinkelbach algorithm.
For the proposed MILFP model, the MILP model implemented in the
Dinkelbach algorithm is given below:
min  AC − f · AP
s.t. Eqs.(1)–(4),  (7)–(10), (13), (15)–(17), (20)–(26),
(28), (31)–(41), (43)–(52), (62)–(105)
(106)
Thus, as shown in Fig. 2, the procedure of the Dinkelbach algo-
rithm for the problem discussed in this work can be implemented
as follows:
Step 1: Initialise f;
Step 2: Solve the MILP model (106), and the obtained values of AC
and AP in the solutions are denoted as AC* and AP*, respectively;
Step 3: If |AC∗ − f · AP∗| ≤ ε, stop and the optimal COG/g =
AC∗/AP∗; otherwise, update f = AC∗/AP∗, then go to Step 2.
It should be noted that in the Dinkelbach algorithm, although
a higher optimality gap of each MILP may  require more iterations
to terminate the algorithm, the optimality gap does not affect the
global optimality of the ﬁnal solution obtained, if it is less than 100%.
The optimal objective value in the last iteration is very close to zero.
Therefore, during last iteration, the upper bound of the objective
value is always positive, while its lower bound is always negative.
The difference between the above two  bounds should always be
larger than 100%, until the objective value reaches below the toler-
ance, ε. Therefore, the optimality gap for the solution of each MILP is
set below 100% and the global optimality is then guaranteed. More
discussion on the optimality gaps will be presented in Section 6.
5. A Case Study
In this section, an industrially-relevant example is considered as
a case study, based on the example of a biopharmaceutical company
using a platform process for mAb  puriﬁcation described by Simaria
et al. (2012). The proposed models and approaches are applied to
this case study to ﬁnd the optimal chromatography step sequencing
and column sizing strategies for the design of a new puriﬁcation
suite in an existing facility.
In this example, we  consider one product, whose process
ﬂowsheet is shown in Fig. 1. There are 6 candidate resins of 5
types, including Afﬁnity Chromatography (AFF), Cation Exchange
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Table 1
Characteristics of the resins in the case study.a
Resin Type Mode Binding
capacity (g/L)
Eluate volume
(CV)
Buffer volume
(CV)
Linear velocity
(cm/h)
Resin lifetime
(cycle)
Resin price
(£/L)
Yield
Capture Intermediate
puriﬁcation
Polishing
R1 AFF Bind-elute 50 2.3 37 150 100 9200 91% 95% –
R2  AFF Bind-elute 30 2.3 37 300 100 6400 91% 95% –
R3  CEX Bind-elute 40 1.4 26 300 100 400 86% 92% 92%
R4  AEX Flow-through 100 0 10 300 100 700 – 95% 95%
R5  MM Flow-through 150 0 10 375 100 3500 – 90% 90%
175 100 2500 – 89% 89%
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Table 4
Cost data in the case study.a
Parameter Value Parameter Value
a (£/L) 14.145 q 1
b  (£/L) 4.234 m  1
c  (£/L) 0.071 mi 0.1
gef  0.7 oe 0.8
gu  (£/L) 90 ma 0.05
lang  6 i 0.005R6  HIC Bind-elute 27.5 1.4 26 
a Simaria et al. (2012).
hromatography (CEX), Anion Exchange Chromatography (AEX),
ixed-Mode Chromatography (MM)  and Hydrophobic Interaction
hromatography (HIC). The details of the resins’ characteristics are
iven in Table 1, from which it can be seen that each candidate
as different suitability and performs differently in terms of yield
hen used in different positions (capture, intermediate puriﬁca-
ion and polishing). The resin utilisation factor () is 0.95, and the
verpacking factor (of) is 1.1.
The candidate values of the chromatography equipment sizing
ecision variables are shown in Table 2. As there are 11 possible
ed heights and 7 possible diameters, single column volume has
7 possible sizes. The number of cycles can be up to 10, while at
ost 4 parallel columns are allowed at each chromatography step.
The main details of the non-chromatographic DSP unit opera-
ions in the process ﬂowsheet used in the model to perform mass
alance and cost calculations are presented in Table 3. The annual
perating time considered in this case study is 340 days. The
atch success rate is 90%. In the USP stage, there are 3 operators
or each bioreactor. In the DSP stage, there are 15 operators per
hift, with a shift pattern of 8 h/day, 7 days/week. The wage for
he operators is £20/h. The media and buffer prices are £32/L and
1/L, respectively. The overﬁll allowance of media, , is set at 1.2.
ore cost data in this case study is shown in Table 4.
able 2
andidate values of the column sizing decisions in the case study.a
Decision Candidate value
Bed height (cm) 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Diameter (cm) 50, 70, 100, 120, 160, 180, 200
Number of cycles 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Number of columns 1, 2, 3, 4
a Simaria et al. (2012)
able 3
haracteristics of non-chromatographic unit operations in the case study.a
Unit operation parameter Value Unit operation parameter Value
Cell culture Virus ﬁltration
Bioreaction time (days) 15 Yield (%) 95
Seed train bioreaction
time (days)
29 Flush volume ratio 0.3
Bioreactor working
volume ratio (%)
75 Processing time (h) 4
Harvest Ultra/diaﬁltration
Yield (%) 95 Yield (%) 90
Flush volume ratio 0.1 Processing time (h) 4
Processing time (h) 4 Final concentration (g/L) 75
Virus inactivation Diaﬁltration volume 7
Yield (%) 90 Bulk ﬁll
Neutralisation volume
ratio
1.75 Yield (%) 98
Processing time (h) 1.5 Filling time (h) 6
a Simaria et al. (2012).s 0.2 t 0.01
a Simaria et al. (2012).
To calculate the ﬁxed capital investment on the bioreactors and
chromatography columns, we use the reference equipment sizes
and costs, and scale-up factors as given in Table 5.
The equipment lifetime is 10 years, and a 10% interest rate is
used. Here, three scenarios of the case study will be investigated,
with different conﬁgurations of USP and DSP trains, i.e., 1USP:1DSP,
2USP:1DSP, and 4USP:1DSP. It is assumed that the total bioreactor
volume is given (25,000 L) and is kept the same for all scenar-
ios. Thus, in the three investigated scenarios, the volumes of each
bioreactor are 25,000 L, 12,500 L, and 6250 L, respectively.
The proposed optimisation model and approach were imple-
mented in GAMS 24.0 (Brooke et al., 2012) on a 64-bit Windows
7 based machine with 3.20 GHz six-core Intel Xeon processor
W3670 and 12.0 GB RAM. Three MINLP solvers, including BARON,
COUENNE and SCIP, were used to solve the MINLP model. CPLEX
was used as the MILP solver to implement the Dinkelbach algo-
rithm. The CPU time for each run was  limited to 1 h.
6. Results and discussion
Firstly, we solved the proposed MINLP model for all three sce-
narios. From Table 6, all three solvers can ﬁnd feasible solutions, but
cannot converge within the CPU time limit. Comparing the three
solvers, SCIP solver always gives solutions that are equal or better
than those from the other two solvers. Then, we investigated the
computational performance of the Dinkelbach algorithm for the
proposed MILFP model. As discussed above, the optimality gap of
each MILP model should be set to less than 100%. Here, we used 6
different gaps for each scenario, including 0%, 5%, 10%, 20%, 50% and
80%. All these gaps ﬁnd the same optimal solutions for all scenarios,
whose optimal objective values are given in Table 6. Comparing the
Table 5
Reference sizes, costs, scale-up factors in the case study.a
Reference size Reference
cost (£)
Scale-up
factor
Bioreactor Volume = 2000 L 612,000 0.6
Chromatography column Diameter = 100 cm 170,000 0.8
a Simaria et al. (2012).
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Fig. 4. CPU times of the Dinkelbach algorithm with different optimality gaps for
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T
Cig. 3. Convergence curves of MINLP and MILFP models for the 1USP:1DSP scenario.
verage CPU time for implementing the Dinkelbach algorithm with
he aforementioned optimality gaps to the CPU times of the MINLP
odels, the Dinkelbach algorithm has a much better computational
erformance than the proposed MINLP model. In the last two  sce-
arios, the CPU time is even improved by one order of magnitude.
urthermore, the 1USP:1DSP scenario was used as an example to
nvestigate the convergence curves of the proposed MINLP models
nd MILFP model, as presented in Fig. 3, in which a 10% optimal-
ty gap is used for the MILP models in the Dinkelbach algorithm.
he Dinkelbach algorithm takes two iterations and 18 CPU seconds
CPUs) to obtain a good feasible solution, whose objective value is
2.38, while the SCIP MINLP solver takes 26 CPUs to ﬁnd a good
easible solution (objective value is 73.69), the fastest among all
hree MINLP solvers. Also, the Dinkelbach algorithm takes about
80 CPUs to obtain the global optimal solution, and for the MINLP
odel, BARON, COUENNE and SCIP solvers take about 850, 1070
nd 2130 CPUs, respectively, to ﬁnd their current best solutions.
hus, the proposed MILFP model is more efﬁcient to ﬁnd good
easible solutions and converge to the optimal solution.
As shown in Fig. 4, the impact of the optimality gap on the
omputational time varies by the scenario investigated. For the
USP:1DSP scenario, a higher gap generally leads to a shorter CPU
ime, except when the gap = 5%, which leads to a longer CPU time
han all other gaps. For the 2USP:1DSP scenario, small gaps (≤10%)
ave similar performance and take longer times than larger gaps
>20%). For the 4USP:1DSP scenario, except for the gaps ≤5%, other
igher gaps have similar performance with CPU times around 500 s.
rom Fig. 4, although a speciﬁc optimality gap with a dominant
dvantage cannot be found, we can still observe that there is con-
istently good performance in all scenarios.
The computational performance of the Dinkelbach algorithm
as analysed. Considering optimality gaps of 0% and 80%, the value
f f found by each iteration is shown in Fig. 5. When optimal-
ty gap = 0%, the Dinkelbach algorithm takes 3 or 4 iterations to
omplete, while more iterations (5 or 6) are required when the
ptimality gap = 80%. Investigating other gaps, we  can ﬁnd that
hen the gap ≤ 5%, the convergence requires 3 to 4 iterations,
nd when the gap ≥ 10%, 5 to 6 iterations are needed to termi-
ate the algorithm. There is signiﬁcant trade-off between the CPU
able 6
omputational performances of MINLP and MILFP models for different USP:DSP scenario
1USP:1DSP 
OBJ CPUs 
BARON 71.8 3600a
MINLP COUENNE 71.5 3600a
SCIP 70.6 3600a
MILFP (Dinkelbach algorithm) 70.2 1680b
a Terminated by CPU time limit.
b Average time with all optimality gaps investigated.Fig. 5. Iterations of the Dinkelbach algorithm for different USP:DSP scenarios when
optimality gap = (a) 0% and (b) 80%.
time per iteration and the number of iterations. Although the CPU
time per iteration decreases when the optimality gap is increased,
the number of iterations increases as well. From Fig. 5, the value of
f decreases signiﬁcantly from iteration 1 to 2, and then it decreases
slightly iteration by iteration until convergence.
s.
2USP:1DSP 4USP:1DSP
OBJ CPUs OBJ CPUs
80.9 3600a 108.4 3600a
82.9 3600a 102.5 3600a
80.9 3600a 95.5 3600a
80.5 794b 95.4 468b
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Fig. 6. Optimal chromatography sequencing decisions for different USP:DSP sce-
narios.
Fig. 7. Optimal column sizing decisions: bed height (x-axis), number of cycles (y-
axis), diameter (proportional to the bubble size, indicated at the centres of the
circles), at (a) capture step; (b) intermediate puriﬁcation step; (c) polishing step,
for  1USP:1DSP (solid circle lines), 2USP:1DSP (dotted circle lines) and 4USP:1DSP
(dash circle lines) scenarios.
Fig. 8. Optimal annual output production and number of completed batches for
different USP:DSP scenarios.Fig. 9. Annual total cost and COG/g for different USP:DSP scenarios.
Next, we investigated the optimal solutions found by the MILFP
model. Fig. 6 shows that for all scenarios, except for the scenario
with 4USP:1DSP, the same resin sequence is selected, i.e., CEX (R3)
for capture, MM (R5) for intermediate puriﬁcation, and AEX (R4)
for polishing. For the scenario with 4USP:1DSP, AFF (R1) is selected
for capture, while CEX (R3) is for intermediate puriﬁcation and AEX
(R4) is for polishing. Thus, the USP:DSP conﬁguration is important
to be investigated, and has an effect on the chromatography step
sequencing decisions.
The optimal chromatography column sizing decisions at each
step are presented in Fig. 7, including the number of cycles per
batch (x-axis), the column bed height (y-axis), the column diam-
eter (proportional to the bubble size, number in cm at the circle
centre). It should be noted that for all scenarios, only one column
is used at each chromatography step. Because both 1USP:1DSP and
2USP:1DSP scenarios have the same chromatography sequence, it
is fair to compare the column sizing decisions of the aforemen-
tioned two  scenarios. As shown in Fig. 7, the number of cycles or
column diameter decrease with the increasing number of bioreac-
tors that lead to decreasing bioreactor size and batch size. Also, for
the above two scenarios, it can be observed that the selected col-
umn  diameters in the subsequent chromatography steps usually
become smaller or not larger, because less protein mass enters into
the subsequent chromatography steps, resulting from the yield at
each manufacturing step.
Fig. 8 shows the optimal annual output and the number of
batches. According to Fig. 8, when the number of bioreactors is
increased, more batches are processed, increasing from 20 batches
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ith one bioreactor to 80 batches with four bioreactors. It should be
oted that although there are more batches with more bioreactors,
atch size becomes smaller. Also, as the ﬁrst two  scenarios select
he same chromatography sequence, their annual productions are
he same, while the 4USP:1DSP scenario has a higher annual pro-
uction, due to the higher yields of the resins selected relative to
he other two  scenarios. An extra 8% of product is obtained in this
cenario.
The breakdown of the total cost for all scenarios is shown in
ig. 9. With increasing number of bioreactors, there is a higher
irect cost, as more batches are produced, and a higher indirect cost
ainly due to the purchase of more equipment. Compared to the
USP:1DSP scenario, the 2USP:1DSP scenario has a higher COG and
he same production output, therefore its COG/g becomes higher,
s shown in Fig. 9. The 4USP:1DSP scenario has both higher COG
nd production output than the other two scenarios. Because the
ncrease in the COG is relatively higher than that in the production
utput, its COG/g is still the highest among all three scenarios.
. Concluding remarks
In this paper, we addressed the integrated optimisation of chro-
atography sequencing and column sizing, extending from our
revious work (Liu et al., 2013b). At ﬁrst, an MINLP model is
eveloped to minimise COG/g. Then, to overcome the computa-
ional expense of the proposed MINLP model, an MILFP model is
eveloped as the reformulation of the MINLP model. The literature
inkelbach algorithm is used as the solution approach of the MILFP
odel. An industrially-relevant example is investigated as the case
tudy. The computational results prove the computational advan-
age of the proposed MILFP model and the Dinkelbach algorithm.
he case study also demonstrated the applicability of the proposed
odels and approaches. Future work will investigate the incorpo-
ation of uncertainty issues and multi-criteria decision-making into
he current work.
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